Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1006
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 913–924 of 1,006 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional Accepts healthy volunteers

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

NCT06120205
Site status not listed — check the official record
View directory record Official record
Conditions
Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
Interventions
Teal Wand Self-Collection Device Group
Device
Lead sponsor
Teal Health, Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping

NCT07009509
Status at this site: Recruiting
View directory record Official record
Conditions
Nicotine Vaping
Interventions
YES-CAN! program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years and older
Enrollment
1,166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Active, not recruiting Phase 1 Interventional

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879
Site status not listed — check the official record
View directory record Official record
Conditions
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
Drug
Lead sponsor
Enliven Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 4 Interventional

Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod

NCT06860633
Status at this site: Recruiting
View directory record Official record
Conditions
Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
Interventions
Efgartigimod
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 2 Interventional

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

NCT04372615
Status at this site: Recruiting
View directory record Official record
Conditions
Autoimmune Encephalitis, Encephalitis
Interventions
Inebilizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Active, not recruiting Not applicable Interventional

Post-Approval Study of the TREO Abdominal Stent-Graft System

NCT04697784
Site status not listed — check the official record
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
TREO Abdominal Stent-Graft System
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 1 Interventional

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT05785754
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
DCSZ11, Pembrolizumab, Doxorubicin, Tebentafusp
Drug
Lead sponsor
DynamiCure Biotechnology
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 3 Interventional

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

NCT05561127
Status at this site: Recruiting
View directory record Official record
Conditions
Bowel; Stricture
Interventions
GIE Medical ProTractX3 TTS DCB, Control
Combination Product · Other
Lead sponsor
GIE Medical
Industry
Eligibility
22 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
32
States / cities
Scottsdale, Arizona • Irvine, California • Lancaster, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 3 Interventional

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

NCT05561114
Status at this site: Recruiting
View directory record Official record
Conditions
Esophageal Stricture
Interventions
GIE Medical ProTractX3 TTS DCB, Control
Combination Product · Other
Lead sponsor
GIE Medical
Industry
Eligibility
22 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246
Site status not listed — check the official record
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response
Interventions
Rucaparib, Nivolumab, Placebo Oral Tablet, Placebo IV Infusion
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
64
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

NCT07030348
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreatic Cancers, Pancreatic Diseases
Interventions
Not listed
Lead sponsor
Do Hyun Park
Other
Eligibility
19 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Nov 5, 2026, 2:33 PM EST

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.